Evidence map›Paper›PMID 41376231›Full record

Trial reportJournal of traditional Chinese medicine = Chung i tsa chih ying wen pan2025

Dongtian Changchun ointment for moderate-to-severe chronic obstructive pulmonary disease: a multicenter, prospective, open-label, randomized controlled trial.

Zhang Yibao, Chen Feng, Sun Meng, Wang Zhenwei, Tang Binqing, Qian Yechang, Jia Wei, Bao Yufang, L I Wenjie, L I Shanqun and 1 more

Abstract readRandomized Controlled TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Zhang YibaoDepartment of Pulmonary Diseases, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 200021, China.
Chen FengDepartment of Pulmonary Diseases, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 200021, China.
Sun MengDepartment of Pulmonary Diseases, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 200021, China.
Wang ZhenweiDepartment of Respiratory Medicine, Yueyang Hospital of Integrated Traditional Chinese and Westem Medicine Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 200083, China.
Tang BinqingDepartment of Respiratory Medicine, Shanghai Municipal Hospital of Traditional Chinese Medicine Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 200071, China.
Qian YechangDepartment of Respiratory Medicine, Shanghai Baoshan Hospital of Integrated Chinese and Western Medicine, Shanghai 201900, China.
Jia WeiDepartment of Respiratory Medicine, Shanghai TCM-integrated hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 200082, China.
Bao YufangDepartment of Respiratory Medicine, Shanghai Pudong TCM Hospital, Shanghai 201299, China.
L I WenjieDepartment of Respiratory Medicine, Shanghai North Station Hospital, Shanghai 200070, China.
L I ShanqunDepartment of Respiratory Medicine, Zhongshan Hospital Affiliated to Fudan University, Shanghai 200032, China.
Zhang WeiDepartment of Pulmonary Diseases, Shuguang Hospital, Shanghai Institute of Infectious Diseases and Biosecurity, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China.

Funding

National Key Research and Development Program of China: Research on the Establishment of Rehabilitation Systems and Strategies for Chronic Obstructive Pulmonary Disease and Clinical Applicability 2018YFC1313600Shanghai Committee of Science and Technology Key Laboratory of Traditional Chinese Medicine Project 20DZ2272200Shanghai Key Clinical Specialty Construction Project Cultivation and Construction Project for the Doctoral Program in Medical Technology shslczdzk05101Shanghai Municipal Science and Technology Major Project: Clinical Research and Evaluation of TCM Diagnosis and Treatment of Sudden Acute Infectious Diseases ZD2021CY001
6 · The paper itself

Abstract

objectiveTo evaluate the clinical efficacy and safety of Dongtian Changchun ointment (, DTCO) for the treatment of patients with stable moderate-to-severe chronic obstructive pulmonary disease (COPD).

methodsThis was a multicenter, prospective, open-label, randomized controlled trial. Patients with COPD who met the inclusion and exclusion criteria were randomly divided into a DTCO group and a control group in a 1∶1 ratio. Both groups were treated with Symbicort Turbuhaler (320 μg / 9 μg twice daily) for 48 weeks. The DTCO group was given additional DTCO (15 g twice daily) for the first 12 weeks. Outcome assessments were conducted at five time points: 0, 12, 24, 36, and 48 weeks. Primary outcome measures included frequency and duration of acute exacerbation of COPD (AECOPD). Secondary outcomes included St. George's Breathing Questionnaire, pulmonary function, 6-min walk test, and modified Medical Research Council (mMRC) scores.

resultsA total of 84 patients were randomly divided into the DTCO group (

conclusionsDTCO significantly reduced the frequency and duration of AECOPD in patients with moderate-to-severe COPD, and demonstrated satisfactory safety.

Indexed as

Drugs, Chinese HerbalPulmonary Disease, Chronic ObstructiveAgedFemaleHumansMaleMiddle AgedOintmentsProspective StudiesTreatment OutcomeDrugs, Chinese HerbalOintmentsacute exacerbationDongtian Changchun ointmentpulmonary disease, chronic obstructiverandomized controlled trial

Identifiers

PMID41376231
PMCPMC12712291

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.